文献速递胸部肿瘤放疗消化道肿瘤放疗

三项前瞻性随机对照肿瘤试验中影响成功入组因素的分析

Analysis of Factors Affecting Successful Clinical Trial Enrollment in the Context of Three Prospective, Randomized, Controlled Trials.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2016-11-27

该研究在2011年6月至2015年3月间,对三项前瞻性随机肿瘤试验(一项寡转移非小细胞肺癌试验,以及两项非小细胞肺癌和食管癌的质子vs调强放疗试验)中309例符合条件患者进行筛查,入组成功率为52%(160例)。入组患者更可能在较早的就诊次数时被介绍试验信息,其他患者特征未显著影响入组成功率。

要点

  • 309例符合条件患者中160例成功入组,入组成功率52%。
  • 较早就诊时介绍试验信息与更高入组率相关:寡转移方案5 vs 3次(P<.001),NSCLC方案4 vs 3次(P=.0018),食管方案3 vs 2次(P=.0086)。
  • 年龄、性别、T/N分期等其他因素未显著影响入组成功率。

核心结论

  • 在难以入组的随机对照试验中,通过更早向患者介绍试验信息可能提高入组率。

研究设计与样本

  • 研究分析了2011年6月至2015年3月期间三项前瞻性 institutional 随机肿瘤试验的筛查和入组数据,共309例符合条件患者被接触。

主要发现

  • 总入组成功率为52%(160/309)。
  • 入组患者更可能在较早的就诊次数时被介绍试验信息:寡转移NSCLC试验为5 vs 3次(P<.001),NSCLC质子vs IMRT试验为4 vs 3次(P=.0018),食管癌质子vs IMRT试验为3 vs 2次(P=.0086)。
  • 未发现其他患者特征或因素显著影响入组成功率。

关键数值与推荐

  • 入组成功率52%(160/309例符合条件患者)。
  • 较早介绍试验信息的就诊次数差异:寡转移方案5 vs 3次(P<.001),NSCLC方案4 vs 3次(P=.0018),食管方案3 vs 2次(P=.0086)。

临床怎么用

  • 在临床实践中,应尽早向符合条件的患者介绍随机对照试验信息,以改善入组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Challenges can arise when attempting to maximize patient enrollment in clinical trials. There have been limited studies focusing on the barriers to enrollment and the efficacy of alternative study design to improve accrual. We analyzed barriers to clinical trial enrollment, particularly the influence of timing, in context of three prospective, randomized oncology trials where one arm was considered more aggressive than the other. METHODS AND MATERIALS: From June 2011 to March 2015, patients who were enrolled on 3 prospective institutional protocols (an oligometastatic non-small cell lung cancer [NSCLC] trial and 2 proton vs intensity modulated radiation therapy trials in NSCLC and esophageal cancer) were screened for protocol eligibility. Eligible candidates were approached about trial participation, and patient characteristics (age, sex, T/N categorization) were recorded along with details surrounding trial presentation (appointment number). Fisher's exact test, Student's t tests, and multivariate analysis were performed to assess differences between enrolled and refusal patients. RESULTS: A total of 309 eligible patients were approached about trial enrollment. The enrollment success rate during this time span was 52% (n=160 patients). Enrolled patients were more likely to be presented trial information at an earlier appointment (oligometastatic protocol: 5 vs 3 appointments [P<.001]; NSCLC protocol: 4 vs 3 appointments [P=.0018]; esophageal protocol: 3 vs 2 appointments [P=.0086]). No other factors or patient characteristics significantly affected enrollment success rate. CONCLUSION: Improvement in enrollment rates for randomized control trials is possible, even in difficult accrual settings. Earlier presentation of trial information to patients is the most influential factor for success and may help overcome accrual barriers without compromising trial design.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Logan JK, Tang C, Liao Z, et al. Analysis of Factors Affecting Successful Clinical Trial Enrollment in the Context of Three Prospective, Randomized, Controlled Trials. Int J Radiat Oncol Biol Phys. 2016. PMID: 28244413. doi:10.1016/j.ijrobp.2016.11.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。